Professor C E Hormaeche (Department of Microbiology, University of Newcastle) explored the subject of live attenuated bacteria as multivalent oral vaccines. Salmonellae harbouring non-reverting mutations in genes of the aromatic pathway (Aro salmonellae) are safe and effective as live oral vaccines for salmonellosis in animals. They are presently undergoing promising human trials. Aro salmonellae expressing recombinant antigens from bacteria, viruses and parasites are also proving effective as live oral multivaccine delivery systems, eliciting humoral, secretory and cellmediated responses to the guest antigens without impairing the ability of the vaccine to protect against salmonellosis. Aro salmonellae expressing fragment C of tetanus toxin (TetC) from anaerobically inductible hcherichia coli nirB promoter are effective experimental live oral typhoid-tetanus vaccines.
The nirB TetC system for the expression of recombinant antigens in Aro salmonellae as C terminal fusions to TetC driven by nirB has been developed further. An Aro salmonella expressing the immunogenic P28 glutathione S-transferase from Schistosoma rnansoni (P28) as a full length fusion to TetC, elicited humoral antibodies to both TetC and P28 as well as IgA to P28. Mice immunized with a single dose of this vaccine were protected against salmonellae, tetanus toxin and experimental infection with Schistosoma mansoni.
The system for the expression of multiple copies of immunogenic epitopes as C terminal fusions to TetC has been further adapted. The immunogenicity of constructs expressing increasing numbers of copies of an epitope from P28 increased with fusions consisting of increasing numbers of copies of the epitope, rather than single copies. The same was true for constructs expressing multiple copies of an immunogenic epitope from herpes simplex virus (HSV) glycoprotein D as fusions to TetC in Aro salmonellae. Mice immunized with constructs expressing multiple copies of the epitope developed antibodies which neutralized HSV in vitro.
Further, mice immunized with a single dose of the vaccine were better protected from challenge with live HSV than normal controls.
The meeting continued with a presentation by Professor D Onions (Department of Veterinary Pathology, University of Glasgow). In some virus infections, particularly those associated with simple RNA viruses, neutralizing antibody directed at capsid proteins or the glycoproteins of the envelope is often the principal barrier to reinfection. For these viruses, an effective immune response may be induced by inactivated or sub-unit vaccines.
However, for more complex viruses an effective immune response requires the induction of an effective cytotoxic Tcell response, often against non-structural regulatory proteins expressed early in the replication cycle. The limitations of sub-unit vaccines for complex viruses has refocused attention on designing live attenuated vaccines by taking advantage of the ,precision that recombinant DNA technology can provide. Viruses with large genomes like herpesviruses, adenoviruses, and poxviruses carry genes that are dispensable for the replication in vitro but play an important role in ensuring their survival and transmission in their natural hosts. Some of these genes also interfere directly with the immune response. Certain a-herpes viruses have captured an interleukin 10 gene from an ancestral host and this virokine favours the production of,$ T H~ driven antibody response at the expense of a cell-mediated response. Not all dispensable genes that govern virulence affect the immune response. In pseudorabies, a herpesvirus infection of pigs, deletion of the gE glycoprotein (HSV nomenclature) attenuates the virus and has the added advantage that vaccinated pigs can be distinguished from wild type infected animals through ELISA assay for gE antibody. Consequently, eradication schemes can be instituted in concert with vaccination. Once these genes are identified they can be inactivated selectively through deletion of their coding regions. In practice, more than one gene is usually deleted. In the case of commercial pseudorabies virus vaccines, this includes the thymidine kinase gene that effects nekovirulence, as well as the gE gene.
For some viruses, the use of live attenuated strains is either not practicable or unsafe. In these instances, viral vectors can be exploited to deliver the appropriate genes. Viral vaccine vectors based on herpesviruses and adenoviruses are under development but amongst the most promising have been those derived from poxviruses. Certain strains of vaccinia and avian poxviruses, particularly canary poxvirus, will infect mammalian cells and enter into abortive replication which fails to produce progeny virons. An advantage of virus vector delivered genes is that their proteins will be presented in association with class I histocompatibility antigens, which is not the case for externally delivered sub-unit vaccines.
The morning session concluded with a paper by Dr E J Stott ( However, subsequent investigation of the immune responses revealed that this protection was due to antibodies to human T-cell components which were present in the vaccines and on the surface of the challenge viruses. Initially seen as a setback, this discovery is now being exploited as a novel alternative approach to vaccination against HIV. Antibody to human MHC class II (HLA DR4) protects macaques against SIV grown in human Cells, and immunization with allogeneic simian lymphocytes protects against SIV grown in simian cells.
Protection has also been induced in the macaque model by vaccination with viral antigens. Although immunization with recombinant envelope proteins rarely protects against infection, it does reduce the virus load in infected macaques. The most impressive protection so far induced in macaques follows infection with attenuated strains of SIV carrying deletions in the non-essential regulatory genes, such as nif.
Animals persistently infected with attenuated SIV resist subsequent challenge with high doses of virulent virus. These animals are also protected against challenge via the rectal mucosa and against challenge with intact virus infected spleen cells. There is some evidence that'protection is not mediated by immune responses in the envelope protein.
Many people are sceptical that an attenuated retrovirus will ever be acceptable as a vaccine. Current efforts are directed towards understanding the protective immune responses induced by live attenuated virus and attempting to reproduce them by less hazardous means. Dr Stott made the point that if this objective proves unobtainable, the safety issues raised by an attenuated retrovirus vaccine must seriously be addressed.
The first paper of the afternoon was given by Professor S Kroll (Department of Paediatrics, St Mary's Hospital) who described the current prospects in the development of vaccines against bacterial meningitis. At present, two species of bacteria Haemophilus irif/uenzae and Neisseria meningitidis are responsible for a Significant number of bacterial meningitis cases reported in the UK. Although a successful vaccine has been developed against H. irif/uenzae, no such vaccine currently exists against N. meningitidis group B. Initially, Professor Kroll described the development of a vaccine against H. irifluenzae which had evolved from the observation that > 95% of invasive H. irifluenzae strains produce a type b polysaccharide capsule. When this polysaccharide is conjugated to a protein carrier such as diphtheria or tetanus toxoid, this antigen is protective. This vaccine is successful in children less than 2 years old, the age group most vulnerable to the disease. Since the introduction of the vaccine in 1992, the incidence of invasive H. irifluenzae type b disease has been reduced by 90%. In addition, the carriage of the organism in the nasopharynx is also reduced in vaccinated children, indicating that eradication of the disease may be possible.
Unfortunately, the search for a vaccine against meningococcal disease has been less successful. Unlike H. irifluenzae three different serogroups are associated with the disease: in Europe group B (70%) and group C (25-30%) predominate. Although some success has been recorded from the immunization of children with polysaccharide from group C organisms, a similar approach using group B polysaccharide has failed. There are structural similarities between group B polysaccharide and neural tissue, consequently this antigen is poorly immunogenic.
At present, the search for a vaccine has centred on the testing of other antigens from meningococcal strains which induce bactericidal antibodies. However, as different serotypes within groups exist, many different antigens may have to be included in a fully protective vaccine. One unique approach taken in Cuba was the use of non-replicating vesicles which naturally bleb from the surface of the organism. These blebs contain many of the different potential protective antigens, and by mixing vesicles from several different strains a multivalent vaccine has been produced. The-Cubans reported very high efficiency for this vaccine. Unfortunately, this success has not been repeated in trials carried out in Norway or Brazil. The reasons for the differences between these trials are not understood but must be resolved if a successful vaccine against group B meningococcal disease is to be developed.
The second speaker of the afternoon was Dr Mark Roberts (Department of Veterinary Pathology, University of Glasgow) who described the development of novel mucosal adjuvants which could be used to induce immune responses against mucosally delivered purified proteins. He stated that mucosal presentation of antigen offered significant advantages over parenteral immunization, including stimulation of both local and systemic arms of the immune system, avoidance of the use of needles and a reduction in potential side effects (such as endotoxin-induced fever). Although much research is at present directed toward the delivery of antigens in living attenuated vectors, difficulties in the cloning and expression of some antigens mean that the development of alternative strategies is essential.
In general, little or no immune response is generated when purified soluble proteins are presented to mucosal surfaces. However, when these antigens are co-administered with either cholera toxin (CT) or heat labile toxin (LT) from E. coli significant local and systemic responses to the normally non-responsive antigen can be detected. Unfortunately, the toxicity of these proteins makes their use in humans unacceptable.
Dr Roberts described genetically detoxified derivatives of two toxins, LT and pertussis toxin (PT), which are able to act as mucosal adjuvants to bystander proteins following intranasal immunization. In the first example, he showed that a non-toxic mutant of LT, described as LT K7,
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enhanced responses to ovalbumin (ova) following intranasal immunization; anti-ova responses were detected in the sera, whereas they were absent in mice immunized intranasally with ova alone. Later he showed that a non-toxic derivative of PT (PT 9K/ 129G) also acted as a mucosal adjuvant. This was tested using fragment C (a non-toxic but protective portion of tetanus toxin) as a bystander antigen. Following a single intranasal dose, significant anti-fragment C responses were induced; such responses were absent in animals immunized with fragment C alone. More significantly, these mice were protected from tetanus toxin challenge. He also showed that the serum IgG and local respiratory tract IgA response to intranasally delivered influenza haem agglutinin was considerably increased if this antigen was coadministered with PT-9K/129G. At present the mechanisms of these proteins are unknown and are currently being actively studied.
Dr D Stanworth (Peptide Therapeutics, Aston Science
Park) described a potential peptide vaccine developed to aid patients with immediate allergic responses such as hay fever and asthma. These responses are dominated by IgE mediated reactions and are believed to be a consequence of allergenmediated cross linkage of IgE molecules on the surface of the mast cells. This is believed to trigger intracellular signalling, which leads to degranulation of the mast cell and release of histamine.
By careful study of the IgE protein and proteins which degranulate mast cells in an IgE independent manner, a base amino-acid domain has been identified on the CH4 chain of the IgE protein, which is essential for activation of mast cell degranulation. Further work has identified a decapeptide within this region, which alone initiates degranulation. The amphipathetic decapeptide is very hydrophobic at the Cterminal and hydrophilic at the N-terminal region. From the crystallographic structure of the IgE molecule, these peptides have been located to a conformationally sensitive region in the IgE molecule. Dr Stanworth proposed that cross-linking of the allergen to the IgE results in conformational changes, allowing insertion of the decapeptide into the membrane of the mast cell where it interacts with cellular proteins, triggering the intracellular signalling leading to degranulation.
Dr Stanworth described several experiments in which immunization with these decapeptides appeared to protect animals against IgE mediated responses. He showed that experimentally sensitized rats which had been immunized with decapeptide were protected against systemic anaphylactic responses following allergen challenge. In addition, histamine release from mast cells taken from these rats 10 min after immunization with allergen was substantially reduced in rats pre-immunized with decapeptide. Similar protective response was observed when rats were passively immunized with a murine monoclonal antibody raised against the human a-chain decapeptide. In addition, mice which have been sensitized to trimellitic anhydride (TMA) by topical application were protected against systemic anaphylaxis (induced by iv injection of TMA-BSA) following passive immunization with the murine monoclonal against the peptide.
These findings have encouraged the development of a decapeptide-protein carrier conjugate which is currently undergoing phase lIII clinical trials. This approach is considered unique as, unlike other attempts at immunological intervention, it is directed against the mast cell triggering sequence. This means that it is independent of the nature of the challenging antigen and one does not have to identify the offending allergen, a real advantage in patients who are often sensitive to many different antigens.
Dr G Cooper (Central Veterinary Laboratory, W eybridge) described how current research. towards the development of a vaccine against salmonella infections in poultry is progressing. Initially, he showed data which emphasized the emergence of foodborne salmonellosis as a worldwide health problem. Industrialization of the production of food of animal origin, he said, has been largely responsible for the emergence of a variety of strains of salmonella in the developed world.
Current vaccine development has been based on the use of environmental strains of S. enteritidis phage type 4 (PT4). This highly virulent clone became more prevalent in the early 1980s and is now responsible for up to 55% of all human cases in the UK. Initial work was based on the development of a live attenuated vaccine strain for use in poultry flocks, a S enteritidis aroA imprecise excision mutant unable to synthesize aromatic amino-acids. This strain was studied for its ability to protect animals against challenge with wild type S. enteritidis. The vaccine strain induced protection of the spleens, livers, and caeca of chickens immunized soon after hatching. In addition, a seeder model was developed in which 3-week-old chickens were challenged orally with a nalidixic-acid-marked strain and introduced to unvaccinated controls and vaccinated chickens. The vaccinated chickens were protected against colonization by the challenge strain.
Dr Cooper said that, in line with the results described for mice, there was no apparent protection in chickens vaccinated orally with a S. enteritidis aroA mutant and challenged with a highly virulent S. tvphimurium strain. However, the challenge dose may have overwhelmed any residual immunity. A genetically defined S. enteritidis aroA candidate strain (CVL30) has been constructed. This strain protected chickens as well as did the original imprecise excision mutant. When newly hatched chickens were vaccinated with strain CVL30 and challenged 24 hours later there was a reduction in colonization of the caeca, perhaps due to competitive exclusion. A S. typhimurium aroA strain has now been constructed from a highly virulent chicken isolate and research is in progress. Strain CVL30 has been administered to over 1000 chickens without apparent reversion to virulence. Passaged isolates analysed by pulsed field gel electrophoresis and PCR were genetically consistent. It is expected that these strains will be te~ted in a field trial in the near future.
Professor G Griffin (St George's Hospital Medical School) concluded the formal presentations of the afternoon with a talk on the development of naked DNA vaccines. He stated that the observation that immune responses could be induced by direct immunization of DNA marked a major advance in the fields of vaccinology.
This work was initially performed in rats, in which plasmid DNA, under the control of powerful eukaryotic promoters (such as luciferase, p-galactosidase and chloramphenicol acetyl transferase) was injected directly into muscle tissue. In the first studies, DNA encoding human dystrophin was used for gene therapy in a rat model for muscular dystrophy. Although the level of expression was not sufficient to repair damage (only about 1% of muscle fibres expressed the protein) expression was sufficient to induce immune responses against the protein. The kinetics of the humoral response to encoded antigens is now well established in this model. Factors affecting the level of immune response generated included the type and the dynamic activity of the muscle tissue to which the DNA is delivered.
One feature of this type of vaccination is the induction of strong T cell responses following immunization. Since it is believed that effective vaccines against viral infections should induce cytotoxic T-cell responses, this approach has provoked considerable interest. As an example, cytotoxic T-cell induction has been described with influenza virus. In these experiments, 100 Jig of influenza A DNA was injected intramuscularly into rats under the control of the RSV (respiratory syncytial virus) promoter. Four weeks after immunization the DNA was stably detected in the muscle and a strong CTL (cytotoxic lymphocyte) response was detected. These animals were protected from challenge against both homologous and heterologous strains of influenza virus. Similarly, high levels of CTLs have been detected against Plasmodium Joelli circumsporozoite protein (PyCSP), an important antigen in mouse malaria.
Additionally, this type of vaccine may prove useful against human tumours, by inducing CTLs against tumour encoded proteins. This is currently being investigated for the treatment of malignant melanoma. It is hoped that patients can be directly immunized through the skin with DNA coated gold particles delivered under high pressure.
At present, only terminally ill patients are being considered as candidates for DNA vaccine trials. However, the potential of this method of vaccination is huge.
At the end of the meeting Professor G Dougan (Imperial College) described the types of vaccines which are currently being considered for development along with some of the commercial considerations which require attention. He then invited the audience to participate in a general discussion.
Initially, the development of DNA vaccines was discussed. The general feeling was one of mistrust, with the potential problem of chromosomal integration highlighted. In addition, concern was voiced about antibodies being raised against self DNA following vaccination. It was felt that this type of vaccination would be suitable only for animals. In defence of the technique, it was argued that gene therapy is already being tried in human beings and that this presents a far greater hazard in terms of autoimmune disease. Also, the consensus was that it would be highly unlikely that antibodies against DNA would develop.
The discussion then turned to whether a successful vaccine against HIV would ever be produced. Was the development of a live attenuated virus for use in humans a possibility? It was felt that although the use of these strains in humans was highly unlikely, they were very important tools in the study of the disease. The recent isolation of attenuated SIV which can protect against wild type challenge shows that immunization against retroviral infection is feasible.
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